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Abstract
The assembly-line synthases that produce bacterial polyketide natural products follow a modular paradigm in which each round of
chain extension is catalysed by a different set or module of enzymes. Examples of deviation from this paradigm, in which a module
catalyses either multiple extensions or none are of interest from both a mechanistic and an evolutionary viewpoint. We present evi-
dence that in the biosynthesis of the 36-membered macrocyclic aminopolyol lactones (marginolactones) azalomycin and
kanchanamycin, isolated respectively from Streptomyces malaysiensis DSM4137 and Streptomyces olivaceus Tü4018, the first
extension module catalyses both the first and second cycles of polyketide chain extension. To confirm the integrity of the azl gene
cluster, it was cloned intact on a bacterial artificial chromosome and transplanted into the heterologous host strain Streptomyces
lividans, which does not possess the genes for marginolactone production. When furnished with 4-guanidinobutyramide, a specific
precursor of the azalomycin starter unit, the recombinant S. lividans produced azalomycin, showing that the polyketide synthase
genes in the sequenced cluster are sufficient to accomplish formation of the full-length polyketide chain. This provides strong
support for module iteration in the azalomycin and kanchanamycin biosynthetic pathways. In contrast, re-sequencing of the gene
cluster for biosynthesis of the polyketide β-lactone ebelactone in Streptomyces aburaviensis has shown that, contrary to a recently-
published proposal, the ebelactone polyketide synthase faithfully follows the colinear modular paradigm.
Introduction
Bacterial modular Type I polyketide synthases (PKSs) are
multienzymes that govern the biosynthesis of diverse complex
polyketide natural products, including clinically useful antibiot-
ics, immunosuppressants, and antitumor compounds. They
follow a remarkable assembly-line paradigm, in which each
cycle of polyketide chain extension is accomplished by a differ-
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ent set or module of vertebrate fatty acid synthase (FAS)-related
enzyme domains [1-4]. The direct connection between the num-
ber and type of modules and the chemical structure of the even-
tual product is often referred to as colinearity. Each module
contains a ketosynthase (KS) domain, which recruits the
growing polyketide acyl chain from the previous module and
catalyses its Claisen-like carbon–carbon bond condensation
with the incoming (alkyl)malonyl extender unit, tethered to an
acyl carrier protein (ACP) domain. The choice of extender unit
installed onto the ACP is dictated by an acyltransferase (AT
domain). In addition to these conserved domains, a module may
contain ketoreductase (KR), dehydratase (DH) and enoyl reduc-
tase (ER) domains that determine the degree and outcome of re-
ductive processing of the newly-formed β-ketoacyl thioester.
Finally, the extended chain is passed on to the following
module. This processive assembly-line operation, in which all
intermediates remain covalently attached to the multienzyme,
helps to explain the efficiency of the process. It also neatly
explains how the diversity of naturally-occurring complex
polyketides is generated by a common biosynthetic mechanism,
and provides clues to the evolution of these multienzymes
through duplication, capture, deletion, and rearrangement of
modules or individual domains [5]. It has both prompted efforts
to manipulate PKS domains and modules into novel
combinations, as a route to obtaining novel non-natural polyke-
tide products [6,7], and facilitated the discovery of new biosyn-
thetic gene clusters using whole-genome sequence analysis
[8,9].
A number of assembly-line PKSs do not exactly follow the
modular colinear paradigm, and there is great interest in charac-
terising such exceptions, both for the insights these examples
can potentially provide into the catalytic mechanism and speci-
ficity of chain extension, and to further our understanding of
how these molecular machines have evolved [10-12]. It is clear,
for example, that a large number of so-called trans-AT PKSs,
where attachment of extender units to ACP domains is effected
by stand-alone AT enzymes rather than by an intramodular AT
domain, have an evolutionary history different from that of
canonical (cis-AT) modular PKSs [13]. In trans-AT PKSs,
domains are often found in unconventional order, and modules
may be split between different PKS multienzyme subunits. In
both types of modular PKS, domains may be present but appar-
ently not used, or expected domains may be missing [10,12].
Perhaps the most striking deviations from colinearity are those
where the number of modules in the PKS does not correspond
to the number of extension units found in the chemical product
[10,12]. Strains subjected either to random mutagenesis or to a
targetted block in post-PKS steps have been found to accumu-
late aberrant products of either PKS module omission ("skip-
ping") or the iterative use of a module ("stuttering") as minor
congeners of a product mixture [14-16]. Efficient skipping of an
interpolated heterologous module has also been observed in an
engineered PKS assembly-line [17,18]. Naturally programmed
skipping of a PKS module to make an alternative product is
rare, the best-characterised example being the production of
both the 12-membered macrolide methymycin and the 14-mem-
bered macrolide pikromycin from the same PKS [19], the
smaller ring arising from use of an alternative start codon
leading to a significantly-truncated final module incapable of
condensation. However, an increasing number of PKS systems
are now known in which the main product apparently requires
iterative use of a module to accomplish two or even three
successive rounds of chain extension. First noted in the stig-
matellin PKS from Stigmatella aurantiaca [20], further exam-
ples have been uncovered in the PKSs for aureothin [21,22],
borrelidin [23,24], lankacidin [25,26], neoaureothin [27],
etnangien [28], crocacin [29], ebelactone [30] and thiolacto-
mycin [31,32]. Given the close mechanistic analogy between
fatty acid synthases and an iterative PKS module, it is instruc-
tive that a normally colinear extension module of the
pikromycin PKS, when studied as a stand-alone protein in vitro,
catalyses two rounds of polyketide chain extension [19]. A
detailed study of the aureothin and neoaureothin PKSs
expressed in a heterologous strain has revealed the role played
both by substrate tolerance of the KS domain in the iterative
module, and by substrate preference in the KS domain of the
downstream module, in favouring longer chains [33,34]. How-
ever, much remains to be learned about the mechanism and
control of iteration, and the degree to which it influences the
structures of complex polyketides.
We aimed to characterise three recently uncovered candidates
for iterative operation within a modular PKS, based on
sequencing of the structural genes showing fewer modules
present in the gene cluster than required to furnish the observed
polyketide. Two of these are the near-identical PKSs (Figure
S1, Supporting Information File 1) for the antifungal 36-mem-
bered marginolactones azalomycin 1a–c (from Streptomyces
malaysiensis  (formerly Streptomyces violaceusniger)
DSM4137) and kanchanamycin 1d [35,36] from Streptomyces
olivaceus Tü4018; and the third is the PKS for the β-lactone
ebelactone, a potent esterase inhibitor from Streptomyces
aburaviensis 2a,b (Figure 1) [30]. These examples are particu-
larly interesting as potential model systems because the chemi-
cal outcome of the two successive extensions catalysed by the
iterative module is predicted to be different (vide infra). We
report here that resequencing of the ebelactone modular PKS
reveals, surprisingly, that it is fully colinear with no need to
invoke iteration. In contrast, the marginolactone PKSs do
appear to employ iteration of a single module within the
assembly-line.
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Figure 1: The structures of marginolactones azalomycin and kanchanamycin, and of the β-lactones ebelactone A and B. The stereocentres of
azalomycin and kanchanamycin are based on bioinformatic prediction [36].
Results and Discussion
Ebelactone A (2a) has been shown, through incorporation of
label from isotopically-labelled precursors, to be constructed
from an acetate starter unit and five propionate units [30,37],
while ebelactone B (2b) arises through the final propionate unit
being replaced by a butyrate unit. The ebelactone PKS is there-
fore expected to contain a loading module and six extension
modules. Draft genome sequencing of the ebelactone-produc-
ing strain Streptomyces aburaviensis ATCC 31860 (NRRL
B-2218) was done as described in the experimental section, and
the ebelactone (ebe) biosynthetic gene cluster (BGC) was locat-
ed in the sequence using the publicly-deposited sequence [30]
as a probe. The organisation of the PKS region was found to
differ significantly from that reported previously. The earlier
work found seven genes encoding PKS proteins, housing a total
of only five extension modules, one of which was split between
multienzymes (a very unusual arrangement for a cis-AT PKS).
To account for the discrepancy, the authors speculated that one
module acts iteratively, in the first cycle without reduction of
the β-ketoacyl-ACP product, and in the second cycle with
reduction of the extended chain to an α,β-unsaturated acyl-ACP.
In contrast, we find that the ebe PKS cluster contains five PKS
genes, the encoded multienzymes together housing one loading
module recruiting and decarboxylating malonyl-CoA [38], and
six extension modules (Table 1).
In fact the domain arrangement within each respective exten-
sion module is precisely that needed to generate the full-length
linear precursor of ebelactone with the exception that the
ketoreductase of module 3 is predicted to be active but is not re-
quired for the production of authentic ebelactone. Such skip-
ping of a single, apparently active domain in a cis-AT PKS is
well-precedented [45-47]. The bioinformatic prediction of the
configuration at each of the seven asymmetric centres was also
in accord with the configuration of authentic ebelactone con-
firmed by total synthesis [48] (Scheme 1). The essentially com-
plete congruence between prediction and the known ebelactone
structure means, unless the clone sequenced here under the
reference number ATCC 31860 is different from that previ-
ously analysed under this same ATCC number [37], that the
previous proposal of iteration may have been based on mis-
assembly of the DNA sequence due to the very high intermod-
ular sequence identity. The ebelactone PKS from our data is
faithfully colinear.
We have previously reported the DNA sequence of both the
azalomycin (azl) and kanchanamycin (kch) clusters [36]. Unlike
ebelactone, these marginolactones undergo late-stage modifica-
tion, including optional mono- or dimethylation of azalomycin
at the guanidino group, and the attachment of a malonyl
sidechain at either C-23 or C-25 (Figure 1). No methyltrans-
ferase or discrete malonyltransferase is encoded within the
respective BGCs. Comparison of the bioinformatic prediction
for either marginolactone with the published structure for these
molecules [36] reveals that although 20 extension modules are
required by the colinear paradigm, only 19 are present. Detailed
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Table 1: The module arrangement of the ebelactone PKS deduced from genome sequence analysis of S. aburaviensis.
Protein Identity number Size (aa) Modules and their domain content Predicted KR typea
EbeA 0356 1055 Loading
KSQ-AT(a)-ACP
–
EbeB 0357 2204 Module 1
KS-AT(p)-DH-ERb-KR-ACP
B1
EbeC 0358 3066 Module 2
KS-AT(p)-KR-ACP-
Module 3
KS-AT(p)-KR-ACP
B2
B2
EbeD 0359 3934 Module 4
KS-AT(p)-DH-KR-ACP-
Module 5
KS-AT(p)-DH-ER-KR-ACP
B1
B1
EbeE 0360 2178 Module 6
KS-AT(p/b)c-KR-ACP-KSd
A2
aThe predicted stereochemical outcome of ketoreduction according to Caffrey [39] and Reid et al. [40], as extended by Keatinge-Clay [41]. KSQ,
KS-like decarboxylase [38] of the PKS loading module. For explanation of other symbols see the text. bThe ER of module 1 has Val at the diagnostic
active site position, predicting 2R configuration at C12 of ebelactone. The ER of module 5 has Tyr at this position, predicting 2S configuration at C4 of
ebelactone [42]. cThe unusual specificity motif in the extender AT of module 6 (VASH) is consistent with utilisation of either methylmalonyl-CoA and
ethylmalonyl-CoA as substrate [43], giving rise respectively to ebelactone A and ebelactone B. dThe C-terminal KS may promote formation of the
β-lactone and chain-release [30,44].
Scheme 1: Comparison of the bioinformatic prediction for ebelactone biosynthesis with the known structure of ebelactone A. The only discrepancy is
that the ketoreductase domain in module 3 is predicted to be active but is not needed to produce ebelactone.
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Scheme 2: Proposed model for iteration of module 1 of AzlA1 in azalomycin biosynthesis. The 4-guanidinobutyryl starter is loaded onto the loading
acyl carrier protein (ACP) by the action of a dedicated acyltransferase (AT) [35]. The starter unit is then transferred from the loading ACP to the
ketosynthase (KS) (step a). In the first cycle of chain extension (step b), the starter is condensed with malonyl-ACP and the resulting β-ketoacyl-ACP
is then reduced by the action of KR and DH, but the ER domain is "skipped". In step c, the extended chain is back-transferred from ACP to the KS. In
the second chain extension (step d), condensation with malonyl-ACP is followed by full reduction. In step e, the triketide chain is transferred to the KS
of module 2 of AzlA2.
comparisons showed the discrepancy to be located at the start of
chain synthesis, where it appears that extension module 1,
housed in PKS multienzyme AzlA1, may catalyse both the first
and second cycle of chain extension (Scheme 2). The same is
true for extension module 1 of the kanchanamycin PKS, housed
in multienzyme KchA1.
In the first cycle, the 4-guanidinobutanoyl starter unit is pro-
posed to condense with malonyl–ACP and the resulting
β-ketoacyl–ACP is then reduced by the action of KR and DH
but the ER domain is "skipped" so an enoyl thioester is pro-
duced. In the second cycle, condensation with a second
malonyl–ACP is followed by full reduction, and then the trike-
tide chain is transferred to the KS of the following module,
module 2. Module 2 is predicted to catalyse addition of a
methylmalonate extension unit and reduction to an enoyl
thioester (the module lacks an ER domain). Puzzlingly, the
structure of azalomycin requires full reduction at this stage.
There is precedent for this, for example in the PKS for the anti-
cancer compound epothilone, where the structure of the prod-
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Figure 2: LC–MS analysis of azalomycin F4a production. a) DSM4137 wild type; b) Δazl (azl disrupted mutant); c) S. lividans ML-A (harbouring the
azl biosynthetic cluster) fed with 4-guanidinobutyramide; and d) S. lividans ML-A not fed with 4-guanidinobutyramide. The two peaks with the same
m/z ([M + H]+ = 1082.6) represent azalomycin F4a isomers, differing in the site of attachment of the malonyl group, either at C23-OH or at C25-OH
[51].
uct requires reduction to an enoyl thioester by module 4 but this
module contains no DH domain [49]. A possible explanation in
both cases is that the missing activity is supplied by an enzyme
domain in a neighbouring module, but this remains to be
demonstrated [10,49].
When the Streptomyces malaysiensis (formerly Streptomyces
violaceusniger) DSM4137 strain was first described, it was re-
ported to produce a different marginolactone called niphimycin
(mol wt 1141.7), which compared to azalomycin has an addi-
tional propionate unit in the sidechain, as well as other minor
differences in the macrocyclic ring [50]. However in our hands
azalomycins F3a (1a, minor) and F4a (1b, major) were pro-
duced. The HRMS of the marginolactone from DSM4137 was
in agreement with that expected for 1b (calcd [M + H]+:
1082.6734, found 1082.6722). Targetted gene-disruption of the
azl PKS genes from the cluster (Figures S2 and S3, Supporting
Information File 1) led to the specific loss of azalomycin pro-
duction, confirming the identity of the cluster (Figure 2a and b).
An alternative explanation to the iterative use of a module
would be the contribution of additional azl PKS multienzymes,
encoded by genes located outside the boundaries of the
sequenced cluster. In the case of stigmatellin this was ruled out
by inactivating all other PKS genes in the genome [52,53] but it
can be done more economically by expression of the gene
cluster in a heterologous host strain [34,54]. Heterologous pro-
duction of azalomycin was carried out by expression of the azl
biosynthetic gene cluster in S. lividans TK24. A clone contain-
ing the azl cluster (~99 kbp), centrally located within a
146.5 kbp insert in the P1-derived bacterial artificial chromo-
some (BAC) vector pESAC13 [55,56] was isolated from a BAC
library of S. malaysiensis DSM4137 genomic DNA as de-
scribed in Supporting Information File 1, and named pYJ2. To
allow the introduction of the cloned azl cluster into actino-
mycete host strains that are intrinsically resistant to thio-
strepton (tsr), the tsr resistance cassette of pYJ2 was replaced
by the apramycin resistance cassette aac(3)IV [57] using
RedET recombineering of pYJ2 in E. coli to generate BAC
clone pML1. Tri-parental mating was used [58] to introduce
pML1 into E. coli ET12567, a triply methylation-deficient
strain that provides higher efficiency of conjugation into many
actinomycete strains. To check for significant deletions in
clones housing the azl genes, PCR primer pairs were designed
that would anneal approximately every 10 kbp within the gene
cluster. The results were fully consistent with the whole gene
cluster being present in E. coli ET12567 containing pML1. This
strain was used for conjugation with S. lividans. Selection for
Beilstein J. Org. Chem. 2016, 12, 2164–2172.
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apramycin resistance led to the isolation of exconjugants, four
of which were analysed using PCR with two flanking and
twelve internal PCR primer pairs. Two colonies were found
which appeared to contain the full azl gene cluster while the
others had apparently suffered deletions at the right end of the
cluster. One of the clones harbouring an apparently intact
cluster was named S. lividans ML-A, and used in further experi-
ments. We have previously shown that the unusual starter unit
in azalomycin biosynthesis, 4-guanidinobutanoyl-CoA, requires
a dedicated three-enzyme precursor pathway: L-arginine is con-
verted by arginine monooxygenase to 4-guanidinobutyramide,
4-guanidinobutyramide hydrolase converts this to 4-guanidi-
nobutyric acid, and the acid is then activated to 4-guanidi-
nobutyl-CoA by 4-guanidinobutanoate:CoA ligase [35]. The
transplanted azl cluster only contains genes for 4-guanidinobu-
tyramide hydrolase gene and 4-guanidinobutanoate:CoA ligase
[36], and the S. lividans genome contains no arginine monooxy-
genase, so we anticipated that heterologous azalomycin produc-
tion would require added 4-guanidinobutyramide. Accordingly,
S. lividans ML-A was grown on SFM agar containing added
4-guanidinobutyramide. After eight days, LC–MS/MS analysis
of a methanol extract of the agar plate showed that azalomycin
F3a, F4a and F5a were produced. No azalomycins were pro-
duced on control plates where 4-guanidinobutyramide was not
present (Figure 2c and d). Also, it appears that the heterologous
host can supply appropriate, as yet unidentified, enzymes to cat-
alyse methylation of the guanidino group and to attach the
malonyl sidechain to the hydroxy group at C-23/C-25. Presum-
ably, these are enzymes acting in primary metabolism and
therefore widely present in actinomycete bacteria. Meanwhile, it
is clear that the PKS genes in the azl cluster as sequenced are
sufficient to accomplish the synthesis of the full-length
azalomycin chain, without requiring any contribution from
addit ional  PKS enzymes encoded elsewhere in the
S. violaceusniger genome. This finding constitutes strong
support for the idea that module 1 of the azalomycin PKS (and
by extension i ts  closely-related counterpart  in the
kanchanamycin PKS) is acting iteratively. In the first cycle,
reduction is halted at the enoyl thioester, while in the second
cycle full reduction is seen. The identity of the ER carrying out
enoylreduction in the third cycle of chain extension remains to
be determined. Experiments to determine the detailed mecha-
nism of iteration on the azalomycin PKS are now in progress.
Conclusion
New exceptions to the so-called colinear rule are of great
interest for our understanding of the paradigm of enzyme catal-
ysis used by bacterial modular PKS multienzymes. As pointed
out by Moss and colleagues in their review of PKS non-colin-
earity [10], the observation of iteration emphasises the close
mechanistic link between chain extension on (wholly iterative)
animal fatty acid synthases and that on bacterial modular
polyketide synthases, and it also hints at what could be a major
mechanism for the evolution of these processive systems.
Nevertheless, the highly repetitive nature of the genes encoding
modular PKS makes it easy to misassemble sequence data, and
prematurely to diagnose a case of programmed iteration. Thus,
the ebelactone PKS, previously reported to be non-colinear
[30], in our hands appears faithfully to follow the modular
colinear paradigm. In contrast, using heterologous expression of
the gene cluster, we have obtained clear evidence for
programmed iteration on the first extension module of the PKS
for the marginolactone azalomycin. Given the identical gene
arrangement in the kanchanamycin gene cluster, we propose
that iteration also operates there.
Supporting Information
Supporting Information File 1
Details of all molecular biological materials and
procedures, growth conditions and analytical data.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-12-206-S1.pdf]
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